Storys zum Thema Enterprises

Folgen
Keine Story zum Thema Enterprises mehr verpassen.
Filtern
  • 07.11.2008 – 12:33

    Residual Risk Reduction Initiative (R3i)

    Media Alert From Residual Risk Reduction Initiative (R3i): 19:00 CST Sunday 9 November 2008

    New Orleans, Louisiana, November 7 (ots/PRNewswire) - - Residual Vascular Risk Reduction: The Global Call to Action - Announcement of the Launch of the Residual Risk Reduction Initiative: R3i KEY FACTS: Residual Risk Reduction Initiative (R3i) calls for action to reduce the lipid related residual vascular risk unaddressed by current standards of care ...

  • 06.11.2008 – 12:35

    Burcon NutraScience Corporation

    Burcon Engages Financial Advisor

    Vancouver, Canada, November 6 (ots/PRNewswire) - Burcon NutraScience Corporation (TSX-V: BU) announces today the appointment of BMO Capital Markets to act as exclusive financial advisor to Burcon in connection with a process to identify and pursue strategic alternatives for the commercialization of its innovative food technology. In engaging BMO Capital Markets, Burcon is initiating an extensive review of alternative strategies for maximizing shareholder value arising ...

  • 06.11.2008 – 07:08

    NAVTEQ Corporation

    NAVTEQ Expands Dynamic Content to Flight Status and Fuel Prices

    Chicago, November 6 (ots/PRNewswire) - - Leveraging Leading Dynamic Distribution Capabilities from Traffic and Camera Alerts NAVTEQ, a leading global provider of digital map data for location-based solutions and vehicle navigation, today announced an exciting expansion to its dynamic content portfolio. Already a leading provider of camera alert data and real-time traffic to navigation systems, NAVTEQ now has ...

  • 05.11.2008 – 18:30

    Boehringer Ingelheim

    Personalising Cancer Care - An Invitation

    Ingelheim, Germany, November 5 (ots/PRNewswire) - - For Non-US Healthcare Media Can the quest for personalised medicine in cancer therapy ever be realised? And how far have we come in the journey to personalised cancer care? What lies ahead from a clinical research perspective will be discussed in an international media webcast entitled "Probable or pipedream: could new cancer targets change the outlook ...

  • 05.11.2008 – 13:36

    Trillium Therapeutics Inc.

    Trillium Strengthens its Board of Directors

    Toronto, November 5 (ots/PRNewswire) - Trillium Therapeutics Inc., a privately held biopharmaceutical company, announced today that industry veterans Dr. Michael Berendt and Dr. John Dietrich have joined its Board as independent directors. Trillium Chairman Dr. Michael Moore commented: "It is a great pleasure to welcome these two experienced biotech executives to the Board where they will enhance our capabilities in ...